Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases

AYDIN, Tuğba

doi:10.4274/meandros.galenos.2021.50251

Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases

Tuğba AYDIN (Atatürk University Faculty of Dentistry, Department of Periodontology, Erzurum, Turkey)

Meandros Medical And Dental Journal

15 0

Yıl: 2021 Cilt: 22 Sayı: 3 Sayfa Aralığı: 242 - 251 Metin Dili: İngilizce DOI: 10.4274/meandros.galenos.2021.50251 İndeks Tarihi: 12-05-2022

Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases

Öz:

Objective: This study aimed to determine oncostatin M (OSM), interleukin-11 (IL11), and leukemia inhibitory factor (LIF) levels in gingival crevicular fluid (GCF), saliva, and serum in periodontally healthy individuals and those with gingivitis (G) and chronic periodontitis (CP) before and after periodontal treatment and to evaluate the relationship between these cytokine levels and clinical periodontal parameters. Materials and Methods: This study involved 24 patients with healthy (H) periodontal tissues, 24 patients with G, and 24 patients with CP. Initially, GCF, saliva, and serum samples were collected, and clinical periodontal measurements, including the plaque index, gingival index, probing depth, and clinical attachment levels, were recorded. At 8 weeks after the initial periodontal treatment, the abovementioned parameters were recorded in the G and CP groups. Cytokine levels were determined using enzyme-linked immunosorbent assay. Results: OSM levels in the GCF, saliva, and serum were significantly higher in the CP group (p<0.05) than in other groups. LIF levels in GCF exhibited a significant increase (p<0.05) in the CP group; however, no significant difference was found in the serum and saliva LIF levels among groups (p˃0.05). IL-11 levels were significantly higher in the CP group (p<0.05) than in other groups, but no significant difference was noted in the serum IL-11 levels among the groups (p˃0.05). Similarly, saliva IL-11 levels were significantly higher in the CP group than in the H group (p<0.05), but they did not show significant difference between the CP and G groups (p˃0.05). Comparative analysis of GCF, saliva OSM, and IL-11 levels in the G and CP groups before and after initial periodontal therapy revealed that they are significantly lower in both groups after therapy (p<0.05). Conclusion: Levels of OSM, LIF, and IL-11 are higher in the G and CP groups, which indicate periodontal tissue destruction. Decreases in IL-11, OSM, and LIF levels after treatment support the idea that initial periodontal therapy can inhibit periodontal tissue destruction.

Anahtar Kelime:

Periodontal Hastalıklı Bireylerde Serum, Tükürük ve Diş Eti Oluğu Sıvısında Onkostatin M, Lösemi İnhibitör Faktör ve İnterlökin-11 Seviyelerinin İncelenmesi

Öz:

Amaç: Bu çalışmanın amacı periodontal açıdan sağlıklı, gingivitisli ve kronik periodontitisli bireylerde tedavi öncesi ve sonrasında diş eti oluğu sıvısı (DOS), serum ve tükürükte onkostatin M (OSM), lösemi inhibitör faktör (LIF) ve interlökin-11 (IL-11) seviyelerini tespit etmek ve klinik periodontal parametreler ile adı geçen bu sitokin seviyeleri arasındaki ilişkiyi araştırmaktır. Gereç ve Yöntemler: Bu çalışmaya 24 periodontal olarak sağlıklı, 24 gingivitisli (G) ve 24 kronik periodontitisli (CP) birey dahil edildi. Başlangıçta tüm gruplardan DOS, serum ve tükürük örnekleri alındı ve plak indeksi (Pİ), gingival indeks (Gİ), sondalanabilir cep derinliği (SCD) ve klinik ataşman kaybı (KAK) değerlerini içeren klinik periodontal ölçümler kaydedildi. G ve CP gruplarında başlangıç periodontal tedaviden 8 hafta sonra veriler tekrar kaydedildi. Sitokin düzeyleri enzime bağlı immünosorbent testi metoduyla saptandı. Bulgular: DOS, serum ve tükürük OSM seviyeleri CP grubunda diğer gruplara göre anlamlı derecede yüksek bulundu (p<0,05). DOS LIF seviyeleri CP grubunda diğer gruplara göre anlamlı derecede yüksek bulunurken (p<0,05), serum ve tükürük LIF seviyeleri gruplar arasında farklılık göstermedi (p>0,05). DOS IL-11 seviyeleri CP grubunda diğer gruplara kıyasla anlamlı derecede yüksek bulundu (p<0,05). Serum IL-11 seviyeleri gruplar arasında farklılık göstermedi (p>0,05). Tükürük IL-11 seviyeleri CP grubunda H grubuna göre anlamlı derecede yüksek bulunurken (p<0,05), G grubu ile fark saptanmadı (p>0,05). G ve CP gruplarında başlangıç periodontal tedavi öncesi ile karşılaştırıldığında, tedavi sonrası DOS ve tükürük OSM ve IL-11 seviyelerinin istatistiksel olarak anlamlı derecede düşük olduğu bulundu (p<0,05). Sonuç: OSM, LIF ve IL-11 seviyelerinin G ve CP gruplarında yüksek bulunması periodontal doku yıkımının mevcudiyetini göstermektedir. Tedavi sonrası OSM, LIF ve IL-11 seviyelerindeki azalma periodontal başlangıç tedavisinin periodontal doku yıkımını engelleyebileceğini desteklemektedir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

References 1. Kornman KS, Page RC, Tonetti MS. The host response to the microbial challenge in periodontitis: assembling the players. Periodontol 2000 1997; 14: 33-53.
2. Hart TC, Kornman KS. Genetic factors in the pathogenesis of periodontitis. Periodontol 2000 1997; 14: 202-15.
3. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. J Periodontal Res 1993; 28: 500- 10.
4. Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease. BMB Rep 2010; 43: 513-23.
5. Rose-John S. Interleukin-6 Family Cytokines. Cold Spring Harb Perspect Biol 2018; 10: a028415.
6. Behrmann I, Hermanns HM, Haan C, Kortylewski M, Radtke S, Greiser J, et al. Signalling of interleukin-6 type cytokines via gp130, leukemia inhibitory factor (LIF) receptor and oncostatin M receptor. Eur Cytokine Netw 2000; 11: 491-2.
7. Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 2000; 43: 281-8.
8. Lin SJ, Chen YL, Kuo MY, Li CL, Lu HK. Measurement of gp130 cytokines oncostatin M and IL-6 in gingival crevicular fluid of patients with chronic periodontitis. Cytokine 2005; 30: 160-7.
9. Martin TJ, Romas E, Gillespie MT. Interleukins in the control of osteoclast differentiation. Crit Rev Eukaryot Gene Expr 1998; 8: 107-23.
10. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 2002; 169: 3353-62.
11. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine 2000; 12: 613-21.
12. Yücel OO, Berker E, Gariboğlu S, Otlu H. Interleukin-11, interleukin-1beta, interleukin-12 and the pathogenesis of inflammatory periodontal diseases. J Clin Periodontol 2008; 35: 365-70.
13. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC Jr, Brinson YS, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 102: 115-23.
14. Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1388-97.
15. Ozmeric N. Advances in periodontal disease markers. Clin Chim Acta 2004; 343: 1-16.
16. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999; 4: 1-6.
17. Kinane DF, Bartold PM. Clinical relevance of the host responses of periodontitis. Periodontol 2000 2007; 43: 278-93. 18. Pan W, Wang Q, Chen Q. The cytokine network involved in the host immune response to periodontitis. Int J Oral Sci 2019; 11: 30.
19. Silva N, Abusleme L, Bravo D, Dutzan N, Garcia-Sesnich J, Vernal R, et al. Host response mechanisms in periodontal diseases. J Appl Oral Sci 2015; 23: 329-55.
20. Lindhe J, Westfelt E, Nyman S, Socransky SS, Haffajee AD. Longterm effect of surgical/non-surgical treatment of periodontal disease. J Clin Periodontol 1984; 11: 448-58.
21. van Oosten MA, Mikx FH, Renggli HH. Microbial and clinical measurements of periodontal pockets during sequential periods of non-treatment, mechanical debridement and metronidazole therapy. J Clin Periodontol 1987; 14: 197-204.
22. Badersten A, Nilvéus R, Egelberg J. Effect of nonsurgical periodontal therapy. I. Moderately advanced periodontitis. J Clin Periodontol 1981; 8: 57-72.
23. Al-Isa M, Alotibi M, Alhashemi H, Althobiani F, Atia A, Baz S. Effect of non-surgical periodontal therapy on the fibrinogen levels in chronic periodontitis patients. Saudi Dent J 2019; 31: 188-93.
24. Afacan B, Öztürk VÖ, Paşalı Ç, Bozkurt E, Köse T, Emingil G. Gingival crevicular fluid and salivary HIF-1α, VEGF, and TNF-α levels in periodontal health and disease. J Periodontol 2019; 90: 788-97.
25. Furuse N, Takai H, Ogata Y. Effects of Initial Periodontal Therapy on Heat Shock Protein 70 Levels in Gingival Crevicular Fluid from Periodontitis Patients. J Clin Med 2020; 9: 3072.
26. Karsiyaka Hendek M, Kisa U, Olgun E. The effect of smoking on gingival crevicular fluid peptidoglycan recognition protein-1 level following initial periodontal therapy in chronic periodontitis. Oral Dis 2020; 26: 166-72.
27. Lee A, Ghaname CB, Braun TM, Sugai JV, Teles RP, Loesche WJ, et al. Bacterial and salivary biomarkers predict the gingival inflammatory profile. J Periodontol 2012; 83: 79-89.
28. Salminen A, Gursoy UK, Paju S, Hyvärinen K, Mäntylä P, Buhlin K, et al. Salivary biomarkers of bacterial burden, inflammatory response, and tissue destruction in periodontitis. J Clin Periodontol 2014; 41: 442-50.
29. Kamma J, Mombelli A, Tsinidou K, Vasdekis V, Giannopoulou C. Cytokines in gingival crevicular fluid of adolescents and young adults. Oral Microbiol Immunol 2009; 24: 7-10.
30. Orozco A, Gemmell E, Bickel M, Seymour GJ. Interleukin 18 and periodontal disease. J Dent Res 2007; 86: 586-93.
31. Pradeep AR, S TM, Garima G, Raju A. Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. Biomarkers 2010; 15: 277-82.
32. Thorat M, Pradeep AR, Garg G. Correlation of levels of oncostatin M cytokine in crevicular fluid and serum in periodontal disease. Int J Oral Sci 2010; 2: 198-207.
33. Becerik S, Öztürk VÖ, Atmaca H, Atilla G, Emingil G. Gingival crevicular fluid and plasma acute-phase cytokine levels in different periodontal diseases. J Periodontol 2012; 83: 1304-13.
34. Naemura JR, Radka SF. Detection of oncostatin M in human plasma and serum by a sensitive enzyme immunoassay. Lymphokine Cytokine Res 1993; 12: 187-90.
35. Sakai A, Ohshima M, Sugano N, Otsuka K, Ito K. Profiling the cytokines in gingival crevicular fluid using a cytokine antibody array. J Periodontol 2006; 77: 856-64.
36. Palmqvist P, Lundberg P, Lundgren I, Hänström L, Lerner UH. IL-1beta and TNF-alpha regulate IL-6-type cytokines in gingival fibroblasts. J Dent Res 2008; 87: 558-63.
37. Kitaura H, Marahleh A, Ohori F, Noguchi T, Shen WR, Qi J, et al. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption. Int J Mol Sci 2020; 21: 5169.
38. Ahlen J, Andersson S, Mukohyama H, Roth C, Bäckman A, Conaway HH, et al. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone 2002; 31: 242-51.
39. Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. J Cell Physiol 1998; 175: 247-54.
40. Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol 2004; 75: 37-43.
41. Yetkin Ay Z, Sütçü R, Uskun E, Bozkurt FY, Berker E. The impact of the IL-11:IL-17 ratio on the chronic periodontitis pathogenesis: a preliminary report. Oral Dis 2009; 15: 93-9.
42. Thorat Manojkumar S, Pradeep AR, Garg G, Raju A. Gingival crevicular fluid levels of oncostatin M in periodontal conditions. Cytokine 2010; 50: 248-52

APA	AYDIN T (2021). Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. , 242 - 251. 10.4274/meandros.galenos.2021.50251
Chicago	AYDIN Tuğba Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. (2021): 242 - 251. 10.4274/meandros.galenos.2021.50251
MLA	AYDIN Tuğba Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. , 2021, ss.242 - 251. 10.4274/meandros.galenos.2021.50251
AMA	AYDIN T Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. . 2021; 242 - 251. 10.4274/meandros.galenos.2021.50251
Vancouver	AYDIN T Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. . 2021; 242 - 251. 10.4274/meandros.galenos.2021.50251
IEEE	AYDIN T "Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases." , ss.242 - 251, 2021. 10.4274/meandros.galenos.2021.50251
ISNAD	AYDIN, Tuğba. "Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases". (2021), 242-251. https://doi.org/10.4274/meandros.galenos.2021.50251

APA	AYDIN T (2021). Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. Meandros Medical And Dental Journal, 22(3), 242 - 251. 10.4274/meandros.galenos.2021.50251
Chicago	AYDIN Tuğba Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. Meandros Medical And Dental Journal 22, no.3 (2021): 242 - 251. 10.4274/meandros.galenos.2021.50251
MLA	AYDIN Tuğba Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. Meandros Medical And Dental Journal, vol.22, no.3, 2021, ss.242 - 251. 10.4274/meandros.galenos.2021.50251
AMA	AYDIN T Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. Meandros Medical And Dental Journal. 2021; 22(3): 242 - 251. 10.4274/meandros.galenos.2021.50251
Vancouver	AYDIN T Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. Meandros Medical And Dental Journal. 2021; 22(3): 242 - 251. 10.4274/meandros.galenos.2021.50251
IEEE	AYDIN T "Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases." Meandros Medical And Dental Journal, 22, ss.242 - 251, 2021. 10.4274/meandros.galenos.2021.50251
ISNAD	AYDIN, Tuğba. "Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases". Meandros Medical And Dental Journal 22/3 (2021), 242-251. https://doi.org/10.4274/meandros.galenos.2021.50251